+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology (Cytogenetic, Biochemical, Molecular Testing), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 270 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830916
The global hereditary testing market size is expected to reach USD 12.73 billion by 2030, registering a CAGR of 8.4% over the forecast period. Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.

The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.

Another important market trend is the growing field of reproductive genetic health. For instance, Natera has seen a consistent increase in test numbers in hereditary illnesses genetic analysis for women's health. This indicates a rise in public acceptance of hereditary testing, which is fueling the market expansion. A rise in the trade of newborn screening equipment has corresponded with a rise in the trade of DNA experiment equipment. Progressing the sharpness of newborn screening all over the world is also assisting in earnings increase. A multigene board trial was formed for introducing genetic melanoma into the clinical application, which has been prompted by changes in genetic experimentation standards. The growing generative hereditary health scope is one of the most important key factors driving the market.

The COVID-19 pandemic had a detrimental impact on the market. For example, after the World Health Organization declared COVID-19 a pandemic, governments all around the world used lockdowns to compel social distancing as a prophylactic measure. In every industry, this resulted in upheaval, constraints, challenges, and adjustments. Similarly, the outbreak has a negative impact on the inherited genetic analysis sector.

Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO solution was introduced by QIAGEN, a business that provides technologies and products for pre-analytical samples and related molecular test solutions. The solution detects immune system T-cell responses to the infection that causes COVID-19. The solution would give precise information on illness development and immunity levels.

Hereditary Testing Market Report Highlights

  • The hereditary cancer testing disease type segment dominated the market with a revenue share of over 80.0% in 2022 and is expected to expand at a significant CAGR over the forecast period. A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer
  • The breast cancer testing segment dominated the hereditary cancer testing market in 2021 owing to its high penetration and increased inheritability. Most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
  • In the hereditary non-cancer testing disease type segment, the cardiac diseases segment is driven by the emergence of high-throughput sequencing, which has resulted in the commercial availability of a significant number of sequencing assays for cardiomyopathies
  • The Non-invasive Prenatal Testing (NIPT) and cancer screening tests segment and the newborn genetic screening segment continue to witness lucrative growth due to the increased adoption across the globe
  • Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in the growth of newborn genetic screening in the hereditary non-cancer testing disease type segment
  • Europe accounted for the largest revenue share of over 34.8% in 2022 owing to the assisted reproductive technology space, coupled with the high penetration of newborn genetic screening
  • Key companies are engaged in securing regulatory approval in emerging countries to expand their business footprint. A substantial number of diagnostic companies have collaborated with technology developers to obtain technology licenses and deliver high-value services to their customers

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Disease Type
1.1.1.2 Technology
1.2 Regional Scope
1.3 Estimates And Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information Or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List Of Secondary Sources
1.11 List Of Abbreviations
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Insights
2.3 Competitive Insights
Chapter 3 Hereditary Testiing Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Increase in sales and demand for DNA test kits
3.3.1.2 Constantly developing commercial landscape of women's reproductive health
3.3.1.3 Decline in sequencing cost & consequent expansion of genetic testing registry
3.3.2 Market restraint analysis
3.3.2.1 Ethical and clinical issues of DNA tests
3.3.2.2 Regulatory challenges pertaining to use of DTC genetic tests
3.3.3 Market Opportunity Analysis
3.3.3.1 Increasing incidence of genetic diseases
3.3.3.2 Presence of demand for early and non-invasive fetal testing procedures
3.3.3.3 Introduction of fragmented point-solutions across the genomics value chain
3.4 Hereditary Testing Market Analysis Tools
3.4.1 Industry analysis - Porter’s
3.4.2 PESTLE Analysis
Chapter 4 Hereditary Testing Market - Segment Analysis, By Disease Type, 2018 - 2030 (USD Million)
4.1 Hereditary Testing Market: Disease Type Movement Analysis
4.2 Hereditary Cancer Testing
4.2.1 Hereditary Cancer Testing market estimates and forecast, 2018 - 2030 (USD Million)
4.2.2 Lung cancer
4.2.2.1 Lung cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.3 Breast cancer
4.2.3.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.4 Colorectal cancer
4.2.4.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.5 Cervical cancer
4.2.5.1 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.6 Ovarian cancer
4.2.6.1 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.7 Prostate cancer
4.2.7.1 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.8 Stomach/gastric cancer
4.2.8.1 Stomach/gastric cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.9 Melanoma
4.2.9.1 Melanoma market estimates and forecast, 2018 - 2030 (USD Million)
4.2.10 Sarcoma
4.2.10.1 Sarcoma market estimates and forecast, 2018 - 2030 (USD Million)
4.2.11 Uterine cancer
4.2.11.1 Uterine cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.12 Pancreatic cancer
4.2.12.1 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Million)
4.2.13 Others
4.2.13.1 Others market estimates and forecast, 2018 - 2030 (USD Million)
4.3 Hereditary Non-cancer Testing
4.3.1 Hereditary Non-cancer Testing market estimates and forecast, 2018 - 2030 (USD Million)
4.3.2 Hereditary genetic testing for cardiac disease
4.3.2.1 Hereditary genetic testing for cardiac disease market estimates and forecast, 2018 - 2030 (USD Million)
4.3.3 Hereditary genetic testing for rare disease
4.3.3.1 Hereditary genetic testing for rare disease market estimates and forecast, 2018 - 2030 (USD Million)
4.3.4 Hereditary genetic testing for other diseases
4.3.4.1 Hereditary genetic testing for other diseases market estimates and forecast, 2018 - 2030 (USD Million)
4.3.2 Newborn genetic screening
4.3.2.1 Newborn genetic screening market estimates and forecast, 2018 - 2030 (USD Million)
4.3.3 Preimplantation Genetic Diagnosis & Screening (PGD/PGS)
4.3.3.1 Preimplantation Genetic Diagnosis & Screening (PGD/PGS) market estimates and forecast, 2018 - 2030 (USD Million)
4.3.4 Non-invasive prenatal testing (NIPT) & carrier screening
4.3.4.1 Non-invasive prenatal testing (NIPT) & carrier screening market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5 Hereditary Testing Market - Segment Analysis, By Technology, 2018 - 2030 (USD Million)
5.1 Hereditary Testing Market: Technology Movement Analysis
5.2 Cytogenetic
5.2.1 Cytogenetic market estimates and forecast, 2018 - 2030 (USD Million)
5.3 Biochemical
5.3.1 Biochemical market estimates and forecast, 2018 - 2030 (USD Million)
5.4 Molecular Testing
5.4.1 Molecular Testing market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6 Hereditary Testing Market - Segment Analysis, By Region, 2018 - 2030 (USD Million)
6.1 Regional Market Snapshot
6.1.1 North America
6.1.1.1 North America hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.2 U.S.
6.1.1.2.1 U.S. hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.2.2 Key country dynamics
6.1.1.2.3 Disease prevalence
6.1.1.2.4 Regulatory framework
6.1.1.2.5 Competitive scenario
6.1.1.3 Canada
6.1.1.3.1 Canada hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.1.3.2 Key country dynamics
6.1.1.3.3 Disease prevalence
6.1.1.3.4 Regulatory framework
6.1.1.3.5 Competitive scenario
6.1.2 Europe
6.1.2.1 Europe hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.2 UK
6.1.2.2.1 UK hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.2.2 Key country dynamics
6.1.2.2.3 Disease prevalence
6.1.2.2.4 Regulatory framework
6.1.2.2.5 Competitive scenario
6.1.2.3 Germany
6.1.2.3.1 Germany hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.3.2 Key country dynamics
6.1.2.3.3 Disease prevalence
6.1.2.3.4 Regulatory framework
6.1.2.3.5 Competitive scenario
6.1.2.4 France
6.1.2.4.1 France hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.4.2 Key country dynamics
6.1.2.4.3 Disease prevalence
6.1.2.4.4 Regulatory framework
6.1.2.4.5 Competitive scenario
6.1.2.5 Italy
6.1.2.5.1 Italy hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.5.2 Key country dynamics
6.1.2.5.3 Disease prevalence
6.1.2.5.4 Regulatory framework
6.1.2.5.5 Competitive scenario
6.1.2.6 Spain
6.1.2.6.1 Spain hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.6.2 Key country dynamics
6.1.2.6.3 Disease prevalence
6.1.2.6.4 Regulatory framework
6.1.2.6.5 Competitive scenario
6.1.2.7 Denmark
6.1.2.7.1 Denmark hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.7.2 Key country dynamics
6.1.2.7.3 Disease prevalence
6.1.2.7.4 Regulatory framework
6.1.2.7.5 Competitive scenario
6.1.2.8 Sweden
6.1.2.8.1 Sweden hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.8.2 Key country dynamics
6.1.2.8.3 Disease prevalence
6.1.2.8.4 Regulatory framework
6.1.2.8.5 Competitive scenario
6.1.2.9 Norway
6.1.2.9.1 Norway hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.2.9.2 Key country dynamics
6.1.2.9.3 Disease prevalence
6.1.2.9.4 Regulatory framework
6.1.2.9.5 Competitive scenario
6.1.3 Asia Pacific
6.1.3.1 Asia Pacific hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.2 Japan
6.1.3.2.1 Japan hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.2.2 Key country dynamics
6.1.3.2.3 Disease prevalence
6.1.3.2.4 Regulatory framework
6.1.3.2.5 Competitive scenario
6.1.3.3 China
6.1.3.3.1 China hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.3.2 Key country dynamics
6.1.3.3.3 Disease prevalence
6.1.3.3.4 Regulatory framework
6.1.3.3.5 Competitive scenario
6.1.3.4 India
6.1.3.4.1 India hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.4.2 Key country dynamics
6.1.3.4.3 Disease prevalence
6.1.3.4.4 Regulatory framework
6.1.3.4.5 Competitive scenario
6.1.3.5 South Korea
6.1.3.5.1 South Korea hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.5.2 Key country dynamics
6.1.3.5.3 Disease prevalence
6.1.3.5.4 Regulatory framework
6.1.3.5.5 Competitive scenario
6.1.3.6 Australia
6.1.3.6.1 Australia hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.6.2 Key country dynamics
6.1.3.6.3 Disease prevalence
6.1.3.6.4 Regulatory framework
6.1.3.6.5 Competitive scenario
6.1.3.7 Thailand
6.1.3.7.1 Thailand hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.3.7.2 Key country dynamics
6.1.3.7.3 Disease prevalence
6.1.3.7.4 Regulatory framework
6.1.3.7.5 Competitive scenario
6.1.4 Latin America
6.1.4.1 Latin America hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.2 Brazil
6.1.4.2.1 Brazil hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.2.2 Key country dynamics
6.1.4.2.3 Disease prevalence
6.1.4.2.4 Regulatory framework
6.1.4.2.5 Competitive scenario
6.1.4.3 Mexico
6.1.4.3.1 Mexico hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.3.2 Key country dynamics
6.1.4.3.3 Disease prevalence
6.1.4.3.4 Regulatory framework
6.1.4.3.5 Competitive scenario
6.1.4.4 Argentina
6.1.4.4.1 Argentina hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.4.4.2 Key country dynamics
6.1.4.4.3 Disease prevalence
6.1.4.4.4 Regulatory framework
6.1.4.4.5 Competitive scenario
6.1.5 MEA
6.1.5.1 MEA hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.2 South Africa
6.1.5.2.1 South Africa hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.2.2 Key country dynamics
6.1.5.2.3 Disease prevalence
6.1.5.2.4 Regulatory framework
6.1.5.2.5 Competitive scenario
6.1.5.3 Saudi Arabia
6.1.5.3.1 Saudi Arabia hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.3.2 Key country dynamics
6.1.5.3.3 Disease prevalence
6.1.5.3.4 Regulatory framework
6.1.5.3.5 Competitive scenario
6.1.5.4 UAE
6.1.5.4.1 UAE hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.4.2 Key country dynamics
6.1.5.4.3 Disease prevalence
6.1.5.4.4 Regulatory framework
6.1.5.4.5 Competitive scenario
6.1.5.5 Kuwait
6.1.5.5.1 Kuwait hereditary testing market estimates and forecast, 2018 - 2030 (USD Million)
6.1.5.5.2 Key country dynamics
6.1.5.5.3 Disease prevalence
6.1.5.5.4 Regulatory framework
6.1.5.5.5 Competitive scenario
Chapter 7 Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 New product launch
7.2.2 Partnerships
7.2.3 Acquisition
7.2.4 Collaboration
7.3 Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Myriad Genetics, Inc.
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic initiatives
7.4.2 Invitae Corporation
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Illumina, Inc.
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic initiatives
7.4.4 Natera, Inc.
7.4.4.1 Company overview
7.4.4.2 Financial performance
7.4.4.3 Product benchmarking
7.4.4.4 Strategic initiatives
7.4.5 Laboratory Corporation of America Holdings
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic initiatives
7.4.6 F. Hoffmann-La Roche Ltd.
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic initiatives
7.4.7 Quest Diagnostics Incorporated
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic initiatives
7.4.8 COOPERSURGICAL, INC.
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic initiatives
7.4.9 Agilent Technologies, Inc.
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic initiatives
7.4.10 Thermo Fisher Scientific, Inc.
7.4.10.1 Company overview
7.4.10.2 Financial performance
7.4.10.3 Product benchmarking
7.4.10.4 Strategic initiatives
7.4.11 Twist Bioscience
7.4.11.1 Company overview
7.4.11.2 Financial performance
7.4.11.3 Product benchmarking
7.4.11.4 Strategic initiatives
7.4.12 SOPHiA GENETICS
7.4.12.1 Company overview
7.4.12.2 Financial performance
7.4.12.3 Product benchmarking
7.4.12.4 Strategic initiatives
7.4.13 Fulgent Genetics
7.4.13.1 Company overview
7.4.13.2 Financial performance
7.4.13.3 Product benchmarking
7.4.13.4 Strategic initiatives
7.4.14 MedGenome
7.4.14.1 Company overview
7.4.14.2 Financial performance
7.4.14.3 Product benchmarking
7.4.14.4 Strategic initiatives
7.4.15 CENTOGENE N.V.
7.4.15.1 Company overview
7.4.15.2 Financial performance
7.4.15.3 Product benchmarking
7.4.15.4 Strategic initiatives
List of Tables
Table 1 Product mapping for hereditary cancer tests
Table 2 DNA sequencing costs over the past decade
Table 3 Global incidence rate of genetic disorders
Table 4 Technology landscape for NIPT tests
Table 5 Comparison of other technologies
Table 6 Countries that prescribe mandatory medical supervision & restriction for genetic tests
Table 7 Susceptibility genes and their prevalence in hereditary ovarian syndromes
Table 8 Various NGS tests for hereditary prostate cancer
Table 9 Genetic testing scenario for patients/families affected by inherited cardiac disease
Table 10 Financial solutions for PGT:
Table 11 Commercial landscape of NIPT for fetal aneuploidy in the U.S.
Table 12 North America hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 13 North America hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 14 North America hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 15 North America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 16 North America hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 17 U.S. hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 18 U.S. hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 19 U.S. hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 20 U.S. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 21 U.S. hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 2 2 Canada hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 23 Canada hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 24 Canada hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 25 Canada hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 26 Canada hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 27 Europe hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 28 Europe hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 29 Europe hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 30 Europe hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 31 Europe hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 32 U.K. hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 33 U.K. hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 34 U.K. hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 35 U.K. hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 36 U.K. hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 37 Germany hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 38 Germany hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 39 Germany hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 40 Germany hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 41 Germany hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 42 France hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 43 France hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 44 France hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 45 France hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 46 France hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 47 Spain hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 48 Spain hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 49 Spain hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 50 Spain hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 51 Spain hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 52 Italy hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 53 Italy hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 54 Italy hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 55 Italy hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 56 Italy hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 57 Denmark hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 58 Denmark hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 59 Denmark hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 60 Denmark hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 61 Denmark hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 62 Sweden hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 63 Sweden hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 64 Sweden hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 65 Sweden hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 66 Sweden hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 67 Norway hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 68 Norway hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 69 Norway hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 70 Norway hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 71 Norway hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 72 Asia Pacific hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 73 Asia Pacific hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 74 Asia Pacific hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 75 Asia Pacific hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 76 Asia Pacific hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 77 China hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 78 China hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 79 China hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 80 China hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 81 China hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 82 Japan hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 83 Japan hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 84 Japan hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 85 Japan hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 86 Japan hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 87 India hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 88 India hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 89 India hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 90 India hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 91 India hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 92 South Korea hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 93 South Korea hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 94 South Korea hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 95 South Korea hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 96 South Korea hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 97 Australia hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 98 Australia hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 99 Australia hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 100 Australia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 101 Australia hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 102 Thailand hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 103 Thailand hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 104 Thailand hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 105 Thailand hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 106 Thailand hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 107 Latin America hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 108 Latin America hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 109 Latin America hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 110 Latin America hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 111 Latin America hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 112 Brazil hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 113 Brazil hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 114 Brazil hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 115 Brazil hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 116 Brazil hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 117 Mexico hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 118 Mexico hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 119 Mexico hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 120 Mexico hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 121 Mexico hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 122 Aergentina hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 123 Aergentina hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 124 Aergentina hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 125 Aergentina hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 126 Aergentina hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 127 MEA hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 128 MEA hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 129 MEA hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 130 MEA hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 131 MEA hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 132 South Africa hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 133 South Africa hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 134 South Africa hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 135 South Africa hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 136 South Africa hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 137 Saudi Arabia hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 142 UAE hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 143 UAE hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 144 UAE hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 145 UAE hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 146 UAE hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
Table 147 Kuwait hereditary testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
Table 148 Kuwait hereditary cancer testing market estimates & forecasts, by type, 2018 - 2030 (USD Million)
Table 149 Kuwait hereditary non-cancer testing market estimates & forecasts, by test type, 2018 - 2030 (USD Million)
Table 150 Kuwait hereditary non-cancer genetic testing market estimates & forecasts, by conditions, 2018 - 2030 (USD Million)
Table 151 Kuwait hereditary testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Hereditary Testing Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2022
Fig. 15 Regional Marketplace: Key Takeaways
Fig. 16 Regional Outlook, 2022 & 2030
Fig. 17 North America Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 18 U.S. Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 19 Canada Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 20 Europe Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 21 Germany Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 22 UK Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 23 France Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 24 Spain Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 25 Italy Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 26 Denmark Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 27 Sweden Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 28 Norway Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 29 Asia Pacific Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 30 Japan Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 31 China Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 32 India Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 33 Australia Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 34 South Korea Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 35 Thailand Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 36 Latin America Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 37 Brazil Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 38 Mexico Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 39 Argentina Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 40 Middle East and Africa Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 41 South Africa Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 42 Saudi Arabia Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 43 UAE Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 44 Kuwait Hereditary Testing Market, 2018 - 2030 (USD Million)
Fig. 45 Global Hereditary Testing Market, for, Hereditary Cancer Testing 2018 - 2030 (USD Million)
Fig. 46 Global Hereditary Testing Market, for, Lung Cancer 2018 - 2030 (USD Million)
Fig. 47 Global Hereditary Testing Market, for, Breast Cancer 2018 - 2030 (USD Million)
Fig. 48 Global Hereditary Testing Market, for, Colorectal Cancer 2018 - 2030 (USD Million)
Fig. 49 Global Hereditary Testing Market, for, Cervical Cancer 2018 - 2030 (USD Million)
Fig. 50 Global Hereditary Testing Market, for, Ovarian Cancer 2018 - 2030 (USD Million)
Fig. 51 Global Hereditary Testing Market, for, Prostate Cancer 2018 - 2030 (USD Million)
Fig. 52 Global Hereditary Testing Market, for, Stomach/Gastric Cancer 2018 - 2030 (USD Million)
Fig. 53 Global Hereditary Testing Market, for, Melanoma 2018 - 2030 (USD Million)
Fig. 54 Global Hereditary Testing Market, for, Sarcoma 2018 - 2030 (USD Million)
Fig. 55 Global Hereditary Testing Market, for, Uterine Cancer 2018 - 2030 (USD Million)
Fig. 56 Global Hereditary Testing Market, for, Pancreatic Cancer 2018 - 2030 (USD Million)
Fig. 57 Global Hereditary Testing Market, for, Others 2018 - 2030 (USD Million)
Fig. 58 Global Hereditary Testing Market, for, Genetic Tests 2018 - 2030 (USD Million)
Fig. 59 Global Hereditary Testing Market, for, Cardiac Diseases 2018 - 2030 (USD Million)
Fig. 60 Global Hereditary Testing Market, for, Rare Diseases 2018 - 2030 (USD Million)
Fig. 61 Global Hereditary Testing Market, for, Other Diseases 2018 - 2030 (USD Million)
Fig. 62 Global Hereditary Testing Market, for, Newborn Genetic Screening 2018 - 2030 (USD Million)
Fig. 63 Global Hereditary Testing Market, for, Preimplantation Genetic Diagnosis & Screening 2018 - 2030 (USD Million)
Fig. 64 Global Hereditary Testing Market, for, Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests 2018 - 2030 (USD Million)
Fig. 65 Global Hereditary Testing Market, for, Cytogenetic 2018 - 2030 (USD Million)
Fig. 66 Global Hereditary Testing Market, for, Biochemical 2018 - 2030 (USD Million)
Fig. 67 Global Hereditary Testing Market, for, Molecular Testing 2018 - 2030 (USD Million)

Companies Mentioned

  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Illumina, Inc.
  • Natera, Inc.
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd.
  • Quest Diagnostics Incorporated
  • COOPERSURGICAL, INC.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience
  • SOPHiA GENETICS
  • Fulgent Genetics
  • MedGenome
  • CENTOGENE N.V.

Methodology

Loading
LOADING...

Table Information